Clinical and progenitor data for CML samples
Clinical status . | No. of samples studied . | Patient age, y . | WBC count, ×109/L . | CFCs/103 CD34+ cells . | LTC-ICs/104 CD34+ cells . | Ph+ LTC-IC samples/total* . |
|---|---|---|---|---|---|---|
| Chronic phase | 18 | 23-56 | 75-640 | 42-120 | 17-1000 | 8/18 |
| Accelerated phase | 8 | 45-71 | 35-460 | 30-160 | 42-480 | 1/8 |
| Blast crisis, myeloid | 2 | 46-60 | 60-110 | 15-50 | ND | ND |
Clinical status . | No. of samples studied . | Patient age, y . | WBC count, ×109/L . | CFCs/103 CD34+ cells . | LTC-ICs/104 CD34+ cells . | Ph+ LTC-IC samples/total* . |
|---|---|---|---|---|---|---|
| Chronic phase | 18 | 23-56 | 75-640 | 42-120 | 17-1000 | 8/18 |
| Accelerated phase | 8 | 45-71 | 35-460 | 30-160 | 42-480 | 1/8 |
| Blast crisis, myeloid | 2 | 46-60 | 60-110 | 15-50 | ND | ND |
CFC and LTC-IC assays were performed as previously described.14 Values for LTC-ICs are the LTC-IC—derived CFC numbers.
ND indicates not done.
LTC-IC was genotyped as Ph- and Ph+ by cytogenetic analysis of Giemsa-banded metaphases from individually processed colonies generated from LTC-IC—derived CFCs.15